Scholars Central

Short communicationPublished Dec 2021

Can Simvastatin reduce COPD exacerbations? A randomized double blind controlled study

Authors: Peter Schenk, Spiel A, Hüttinger F, Gmeiner M, Fugger J, Pichler M, Pichler G, Schmeikal S, Janistyn W, Schügerl S, Sajdik C, Herkner H

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Several studies have shown that statins have beneficial effects in chronic obstructive pulmonary disease (COPD) regarding lung function decline, rates and severity of exacerbations, hospitalization and need for mechanical ventilation. We performed a randomized double-blind placebocontrolled single-center trial of simvastatin at a daily dose of 40 mg versus placebo in patients with Global Initiative for COPD criteria II-IV at a tertiary care pulmonology department in Austria. Scheduled treatment duration was 12 months and main outcome parameter was time to first exacerbation. Overall, 209 patients were enrolled. In the 105 patients taking simvastatin, time to first exacerbation was significantly longer compared to the 104 patients taking placebo: median 341 vs. 140 days, log-rank test p < 0.001. Hazard ratio for risk of first exacerbation for the simvastatin group was 0.51 (95% CI 0.34 – 0.75; p = 0.001). Rate of exacerbations was significantly lower with simvastatin: 103 (41%) vs. 147 (59%), p = 0.003. The annualized exacerbation rate was 1.45 per patient-year in the simvastatin group and 1.9 in the placebo group (IRR 0.77, 95% CI 0.60 to 0.99). We found no effect on quality of life, lung function, six-minute walk test and high-sensitivity C-reactive protein. More patients dropped out in the simvastatin group compared to the placebo group (39 vs. 29). In our single-center RCT, simvastatin at a dose of 40 mg daily significantly prolonged time to first COPD exacerbation and reduced exacerbation rate.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Pulmonary Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pulmonary Medicine
  • SubjectPulmonology & Respiratory
  • BylineArticles whose byline prints “Peter Schenk”
  • BylineArticles whose byline prints “Spiel A”
  • BylineArticles whose byline prints “Hüttinger F”
  • BylineArticles whose byline prints “Gmeiner M”
  • BylineArticles whose byline prints “Fugger J”
  • BylineArticles whose byline prints “Pichler M”
  • BylineArticles whose byline prints “Pichler G”
  • BylineArticles whose byline prints “Schmeikal S”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels